Please select the eligibility criteria that correspond to the clinical trial below.
Title: PeriOperative ISchemic Evaluation-3 Trial
Brief Summary: This study is a multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy.


Options:
A: Inclusion Criteria:

* gestational age between 37 and 42 weeks,
* live fetus,
* cephalic presentation,
* vaginal birth.
* Patients who had a risk factors for PPH, such as multiple gestation, polyhydramnios, fetal macrosomia, antepartum hemorrhage, anemia (haemoglobin concentration \< 8 g/dL), severe pre-eclampsia, or coagulopathy

Exclusion Criteria:

* placenta previa,
* placental abruption,
* cesarean section or any uterine scar, abnormal placentation (accreta, increta, or percreta),
* a current or previous history of significant disease, including heart disease, liver, renal disorders.
B: Inclusion Criteria:

* Pregnant women candidate for LSCS.
* Age: 20-40 years old.
* Full term pregnancies (\> 37 weeks confirmed by the 1st day of the LMP or 1st trimesteric ultrasound scan).
* Singleton or twin pregnancies.
* Maternal Anemia (hemoglobin \< 9.9 g%)
* Maternal medical disorders (e.g. cardiac, renal, and hepatic diseases, Thromboembolic disorders or coagulopathies).
* High risk case for obstetric hemorrhage (e.g. peripartum hemorrhage, accidental hemorrhage, placenta previa, previous history of uterine atony or postpartum hemorrhage).
* CS under spinal anesthesia.

Exclusion Criteria:

* Fetal death (IUFD).
* Fetal anomalies or IUGR (estimated fetal weight below the 5th centile)
* Women attending for emergency CS.
* More than 2 previous CS procedures.
* Prolonged procedure (more than 2 hours from skin incision to skin closure).
* History of prostaglandin or Tranexamic acid allergy.
C: Inclusion criteria:

1. Undergoing noncardiac surgery;
2. ≥ 45 years of age;
3. Expected to require at least an overnight hospital admission after surgery;
4. Provide written informed consent to participate in the POISE-3 Trial, AND
5. Fulfill ≥1 of the following 6 criteria (A-F):

A. NT-proBNP ≥200 ng/L B. History of coronary artery disease C. History of peripheral arterial disease D. History of stroke E. Undergoing major vascular surgery; OR F. Any 3 of 9 risk criteria i. Undergoing major surgery; ii. History of congestive heart failure; iii. History of a transient ischemic attack; iv. Diabetes and currently taking an oral hypoglycemic agent or insulin; v. Age \>70 years; vi. History of hypertension; vii. Serum creatinine \> 175 µmol/L (\> 2.0 mg/dl); viii. History of smoking within 2 years of surgery; ix. Undergoing emergent/urgent surgery.

Exclusion criteria:

1. Patients undergoing cardiac surgery
2. Patients undergoing cranial neurosurgery
3. Planned use of systemic TXA during surgery
4. Low-risk surgical procedure (based on individual physician's judgment)
5. Hypersensitivity or known allergy to TXA
6. Creatinine clearance \<30 mL/min (Cockcroft-Gault equation) or on chronic dialysis
7. History of seizure disorder
8. Patients with recent stroke, myocardial infarction, acute arterial thrombosis or venous thromboembolism (\<3 month)
9. Patients with fibrinolytic conditions following consumption coagulopathy
10. Patients with subarachnoid hemorrhage within the past 30 days
11. Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
12. Previously enrolled in POISE-3 Trial
D: Inclusion Criteria:

* 18 years of age or older
* Singleton pregnancy
* Confirmed pregnancy
* Gestational age \>32\^0/7 weeks

Exclusion Criteria:

* Lack of patient consent
* Multiple pregnancy
* History of eclampsia or preeclampsia in current pregnancy
* Imminent Delivery as suspected by any RN or MD involved in delivery care
* History of cardiovascular complications:

  * Coronary artery disease or myocardial infarction
  * Repaired or unrepaired congenital heart disease
  * Vascular disease(s)
  * Severe unstable arrhythmia (e.g. Rapid atrial fibrillation, paroxysmal fibrillation, atrial flutter, etc.)
  * Congestive heart failure
* Contraindication to TXA:

  * History of venous thromboembolism
  * Active thromboembolic disease
  * High risk of thrombosis (e.g. Factor V Leiden or Protein C deficiency)
  * Acquired disturbances of colour vision
  * Allergy to TXA
  * History of seizure disorder
  * Pre-existing hematuria
  * History of renal insufficiency
* Unlikely to comply with follow-up (e.g. no fixed address, plans to move out of town)
* Prisoner status

Answer: C